Scientific Programme

4th GA2LEN Global Urticaria Forum

as of 7 November 2018

Wednesday, 5 December 2018

09:00-10:30 UCARE Business Meeting
Download Meeting Agenda
10:45-11:15 Workshop Faculty Briefing Session

10:00-11:15

Registration

11:30-11:45

Welcome, introduction and objectives

Ana Giménez-Arnau

Marcus Maurer

Torsten Zuberbier

11:45-12:15

Autoallergy - hot or hype?

(Chairs: Emek Kocatürk, Martijn van Doorn)

Marcus Maurer

Session I

Oral presentations: The aetiopathogenesis of urticaria

(Chairs: Iman Nasr, Jonny Peter, Solange Valle)

12:15-12:35 What causes chronic urticaria?

Michihiro Hide

Torsten Zuberbier

12:35-12:44 OP.001 The relationship between chronic spontaneous urticaria with microrna-221 and microrna-155 Ozge Sevil Karstarl Bakay
12:44-12:53 OP.002 Effects of VEGF, IL-1 and TNF-Alpha on TF-expression of HUVECs Akiko Kamegashira
12:53-13:02 OP.003 Cholinergic dermalgia: Is this a subtype of cholinergic urticaria? Shunsuke Takahagi
13:02-13:11 OP.004 Platelet activating factor receptor (PAF-R) in chronic spontaneus urticaria (CSU) Evelyn Andrades
13:11-13:20

OP.005 Tumor necrosis factor-alpha and Fas/Fas ligand signaling pathways in patients with chronic spontaneous urticaria

Agnieszka Skrzypulec-Frankel
13:20-14:20 Lunch Break

Session II

Oral presentations: Urticaria endotypes, diagnostic approaches and biomarkers

(Chair: Roberta Jardim Criado)

 
14:20-14:40 The spectrum of chronic urticaria

Clive Grattan

Petra Staubach

14:40-14:49 OP.006 Immunologic changes during omalizumab treatment in chronic spontaneous urticaria patients Chiara Tontini
14:49-14:58 OP.007 Efficacy of omalizumab-treatment in CSU correlates with reduced T-cell subsets Michèle Myriam Rauber
14:58-15:07 OP.008 Semaphorin5A and IL-17 are important players in the pathogenesis of chronic spontaneous urticaria Zahava Vadasz
15:07-15:16 OP.009 Serum miR-125a-5p elevates in chronic spontaneous/idiopathic urticaria Ting Xiao
15:16-15:25 OP.010 The urticaria control test for monitoring CIU treatment: XTEND-CIU results Allen Kaplan
15:25-15:55

Recurrent angioedema - status quo & quo vadis

(Chairs: Laurence Bouillet, M. Sendhil Kumaran)

Bruce Zuraw
15:55-16:20 Coffee Break

Workshops

(All participants do all workshops, participants rotate)

16:20-16:50

Workshop I: UCARE Projects

 

 

 

 

 

Workshop II: PROMs - How to use patient reported outcome measures?

Ivan Cherrez

Aurélie Du-Thanh

Emek Kocatürk

Désirée Larenas Linnemann

 

Simon Francis Thomsen (Chair)

Karsten Weller (Chair)       

Gustavo Deza

Alicia Kasperska-Zajac

Karoline Krause

Kanokvalai Kulthanan

Markus Magerl

Melba Munoz-Roldan

Frank Siebenhaar

Dorothea Terhorst-Molawi

Hilary Longhurst

Carolina Vera

17:00-17:30

 

Workshop I: UCARE Projects

 

 

 

 

 

Workshop II: PROMs - How to use patients reported outcome measures?

Ivan Cherrez

Aurélie Du-Thanh

Emek Kocatürk

Désirée Larenas Linnemann

 

Simon Francis Thomsen (Chair)                  

Karsten Weller (Chair)                    

Gustavo Deza

Alicia Kasperska-Zajac

Karoline Krause

Kanokvalai Kulthanan

Markus Magerl

Melba Munoz-Roldan

Frank Siebenhaar

Dorothea Terhorst-Molawi

Hilary Longhurst

Carolina Vera

Session III

Oral presentations: Recent insights on chronic urticaria from clinical trials and studies

(Chair: Zuotao Zhao)

17:35-17:55 My top 10 learnings from recent and ongoing urticaria studies

Martin Metz

Gordon Sussman

17:55-18:04 OP.011 Next generation anti-IgE antibody Ligelizumab in CSU: Phase 2b results Marcus Maurer
18:04-18:13 OP.012 Azathioprine versus cyclosporine in steroid dependent chronic refractory urticaria Muthu Sendhil Kumaran
18:13-18:22 OP.013 Omalizumab is effective in symptomatic dermographism: a prospective clinical analysis Yudi Chen
18:22-18:31 OP.014 Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria
Heike Röckmann
18:31-18:40 OP.015 Use of H1-antihistamines during omalizumab treatment Luis Felipe Ensina
18:41-18:50
OP.016 Real life treatment with omalizumab is safe and effective in patients with cholinergic urticaria
Sabine Altrichter
Followed by Scientific Dinner

Thursday, 6 December 2018

08:15-08:30

Registration

08:30-08:45 Welcome

Ana Giménez-Arnau

Marcus Maurer

Torsten Zuberbier 

Session IV

Oral presentations: Urticaria treatments and predictors of response

(Chairs: Daria Fomina, Iris Medina)

08:45-09:05

Urticaria treatment - What works and why

Martin Church

Sarbjit Saini

09:05-09:14 OP.017 Efficacy and safety of omalizumab for cholinergic urticaria in patients who are unresponsive to a double dose of antihistamines Marta Ferrer
09:14-09:23 OP.018 AK002, a Siglec-8 antibody, inhibits mast cells and depletes eosinophils

Henrik Rasmussen

Bhupinder Singh

09:23-09:32
OP.019 FceRI-bearing leukocytes in response to omalizumab treatment in chronic spontaneous urticaria Mehran Alizadeh Aghdam
09:32-09:41 OP.020 Effect of probiotic supplementation on disease activity and quality of life of patients with chronic spontaneous urticaria Pelin Kuteyla Can
09:41-09:50 OP.021 Multi-centre experience of home omalizumab treatment for chronic spontaneous urticaria Sarah Denman
09:51-10:00 OP.022 Basophil high-affinity IgE receptor expression in patients with chronic urticaria Clara Ribas-Lauradó
Poster Session
10:00-11:10

Guided posterwalks on

1) Urticaria Pathogenesis

2) Urticaria Biomarkers, predictors of the course of disease and response to treatment

3) Urticaria Clinical trials and studies

4) Urticaria Differential Diagnoses

5) Urticaria Treatment

6) Recurrent Angioedema

7) Urticaria Special Interest 1

8) Urticaria Special Interest 2

Moshe Ben-Soshan

Margarida Goncalo

Tabi Leslie

Alexander Marsland

Michael Rudenko

Christian Vestergaard

Bettina Wedi

Karoline Krause

11:10-11:35 Coffee Break

Workshops

(All participants do all workshops, participants rotate)

11:35-12:05

Workshop III: CINDU - How to diagnose and monitor inducible urticaria?

 

 

 

 

 

 

 

 

 

 

 

 

Workshop IV: CURE - The chronic urticaria registry

Sabine Altrichter (Chair)

Tomasz Hawro (Chair)   

Mojca Bizjak

Hanna Bonnekoh

Thomas Buttgereit

Emek Kocatürk

Pavel Kolkhir

Leonor Carneiro Leao

Hermenio Lima

Raisa Meshkova

Hanna Siiskonen

Vasiliki Zampeli

 

Pascale Mathelier-Fusade

Karsten Weller

12:15-12:45

Workshop III: CINDU - How to diagnose and monitor inducible urticaria?

 

 

 

 

 

 

 

 

 

 

 

Workshop IV: CURE - The chronic urticaria registry

Sabine Altrichter (Chair)

Tomasz Hawro (Chair)

Mojca Bizjak

Hanna Bonnekoh

Thomas Buttgereit

Emek Kocatürk

Pavel Kolkhir

Leonor Carneiro Leao

Hermenio Lima

Raisa Meshkova

Hanna Siiskonen

Vasiliki Zampeli

 

Pascale Mathelier-Fusade

Karsten Weller

Interactive Case Journey
12:55-13:40 Problems you like, solutions you're looking for

facilitators:

Karoline Krause

Frank Siebenhaar

Faculty:

Karla Arruda

Riccardo Asero

Kiran Godse

Allen Kaplan

Elias Toubi

13:40-14:40 Lunch Break
Session V

Oral presentations: Recurrent angioedema,
differential diagnoses, comorbidities

(Chairs: Michael Makris, Michèle Myriam Rauber)

14:40-15:00 Recurrent Angioedema - What we know and what we don't know

Isabelle Boccon Gibod

Markus Magerl

15:00-15:09 OP.023 Bradykinin mechanism is the main responsible for death by asphyxiating angiodema in France Laurence Bouillet
15:09-15:18 OP.024 BECK depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria and presence of depression might impair response to omalizumab Emek Kocatürk
15:18-15:27 OP.025 Continuous effectiveness of canakinumab treatment in Schnitzler’s syndrome: a 4-year open-label multi-center study Karoline Krause
15:27-15:36 OP.026 A novel urticarial and Factor XII mutation-related autoinflammatory syndrome Niklas Mahnke
15:36-15:45 OP.027 Neutrophil extracellular traps in Schnitzler’s syndrome Hanna Bonnekoh
15:45-16:15

The future of urticaria therapy - novel targets, better treatment

(Chair: Kemal Özyurt)

Ana Giménez-Arnau
16:15-16:25 Good byes

Ana Giménez-Arnau

Marcus Maurer

Torsten Zuberbier

Certification

The 4th GA²LEN Global Urticaria Forum 2018, Berlin, Germany, 05/12/2018-06/12/2018 has been
accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with
9 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit
that he/she actually spent in the educational activity. Certificates will be sent to each participant after the meeting.

The Meeting will be also certified by the Ärztekammer Berlin with 12 CME credits. Certificates will be distributed at the end of the meeting.

 

 

Photo Gallery 2018

Cooperating Organisations

Professional Congress Organiser

Remember Management GmbH
Albrechtstr. 14b, D-10117 Berlin
Phone: +49 30 47 37 25 77
E-mail: guf(at)remember-management.de
www.remember-management.de